Immunoexpression of the CD30 ligand/CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases

Histology and Histopathology

Volumn 21, Issue 1-3, 2006, Pages 249-256

  Ruggeri, R M ^a   Barresi, G ^a   Sciacchitano, S ^b,c   Trimarchi, F ^a   Benvenga, S ^a,d   Trovato, Maria ^a,d  

^a UNIVERSITY OF MESSINA   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Autoimmunity; CD30; CD30 ligand; IL 6; IL 6 receptor; Immunohistochemistry; Thyroid

Indexed keywords

CD30 ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; THIAMAZOLE;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MALE; MYASTHENIA GRAVIS; PATHOGENESIS; PHENOTYPE; THYROIDECTOMY; TISSUE SECTION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD30; AUTOIMMUNITY; CD30 LIGAND; CELL AGGREGATION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LYMPHOCYTES; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; TH2 CELLS; THYROID GLAND; TUMOR NECROSIS FACTORS;

EID: 29844439694     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ajjan R.A., Watson P.F., McIntosh R.S. and Weetman A.P. (1996). Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin. Exp. Immunol. 105, 523-528.
2. Burman K.D. and Baker J.R. Jr. (1985). Immune mechanisms in Graves' disease. Endocr. Rev. 6, 183-232.
3. Chiovato L., Bassi P., Santini F., Mammoli C., Lapi P., Carayon P. and Pinchera A. (1993). Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. J. Clin. Endocrinol. Metab. 77, 1700-1705.
4. Croft M. (2003). Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 8, 609-620.
5. Del Prete G., De Carli M., D'Elios M.M., Daniel K.C., Almerigogna F., Alderson M., Smith C.A., Thomas E. and Romagnani S. (1995). CD30-mediated signaling promotes the development of human T helper type-2-like T cells. J. Exp. Med. 182: 347-351.
6. Doniach D. and Roitt I.M. (1976). Autoimmune thyroid disease. In: Textbook of immunopathology. Miescher P.A. and Muller-Eberhard H.J. (eds). Grune and Stratton. New York. pp 715-736.
7. Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B. and Stain H. (1992). Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68, 421-427.
8. Falini B., Bolognesi A., Flenghi L., Tazzari P.L., Broe M.K., Stein H., Durkop H., Aversa F., Corneli P., Pizzolo G., Barbabietola G. and Sabattini E. (1992). Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339, 1195-1196.
9. Falini B., Pileri S., Pizzolo G., Durkop H., Flenghi L., Stirpe F., Martelli M.F. and Stein H. (1995). CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85, 1-14.
10. Gerli R., Lunardi C., Vinante F., Bistoni O., Pizzolo G. and Pitzalis C. (2001). Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 22, 72-77.
11. Gown A.M., deWever N. and Battifora H. (1993). Microwaved-based antigen unmasking. A revolutionary new technique for routeine immunohistochemistry. Appl. Immunohistochem. 1, 256-266.
12. Grubeck-Loebenstein B., Buchan G., Chantry D., Kassal H., Londei M., Pirich K., Barrett K., Turner M., Waldhausl W. and Feldmann M. (1989). Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. Clin. Exp. Immunol. 77, 324-330.
13. Gruss H.J., Boiani N., Williams D.E., Armitage R.J., Smith C.A. and Goodwin R.G. (1994). Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83, 2045-2056.
14. Gruss H.J., Pinto A., Gloghini A., Wehnes E., Wright B., Boiani N., Aldinucci D., Gattei V., Zagonel V., Smith C.A., Kadin M.E., von Schilling C., Goodwin R.G., Herrmann F. and Carbone A. (1996). CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am. J. Pathol. 149, 469-481.
15. Harii N., Lewis C.J., Vasko V., McCall K., Benavides-Peraira U., Sun X., Ringel M.D., Saji M., Giuliani C., Naolitano G., Goetz J. and Kohn L.D. (2005). Thyrocytes express a funztional Toll-Like Receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis. Mol. Endocrinol. 19, 1231-1250.
16. Hibi M., Murakami M., Saito M., Hirano T., Taga T. and Kishimoto T. (1990). Molecular cloning and expression of an IL-6 signal trasducer, gp130. Cell 63, 1149-1157.
17. Hirano T. (1998). Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. 16, 249-284.
18. Jones T.H. (1994). Interleukin-6 an endocrine cytokine. Clin. Endocrinol. 40, 703-713.
19. Kallen K.J. (2002). The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta 1592, 323-343.
20. Kayser L., Broholm H., Francis D., Perrild H., Olsen B.E., Bendtzen K. and Hoyer P.E. (1995). Immunocytochemical localisation of interleukin-1 alpha and interleukin-6 in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders. Autoimmunity 20, 75-82.
21. Kishimoto, T., Akira S. and Taga T. (1992). Interleukin-6 and its receptor: a paradigm for cytokines. Science 258, 593-597.
22. Li Volsi V. (1990). Lymphocytes in the thyroid. In: Surgical pathology of the thyroid. Li Volsi V. (ed). W.B. Saunders Company. Philadelphia. pp 68-97.
23. Matthey B., Borchmann P., Schnell R., Tawadros S., Lange H., Huhn M., Klimka A., Tur M.K., Barth S., Engert A. and Hansen H.P. (2004). Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int. J. Cancer 111, 568-574.
24. Okumura M., Hidaka Y., Kuroda S., Takeoka K., Tada H. and Amino N. (1997). Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab. 82, 1757-1760.
25. Paschke R., Schuppert F., Taton M. and Velu T. (1994). Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J. Endocrinol. 141, 309-315.
26. Phenekos C., Vryonidou A., Gritzapis A.D., Baxevanis C.N., Goula M. and Papamichail M. (2004). Th1 and Th2 Serum Cytokine Profiles Characterize Patients with Hashimoto's Thyroiditis (Th1) and Graves' Disease (Th2). Neuroimmunomodulation 11, 209-213.
27. Ruggeri R.M., Villari D., Simone A., Scarfi R., Attard M., Orlandi F., Barresi G., Trimarchi F., Trovato M. and Benvenga S. (2002). Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor. J. Endocrinol. Invest. 25, 959-966.
28. Schnell R., Borchmann P., Schulz H. and Engert A. (2002). Current strategies of antibody-based treatment in Hodgkin's disease. Ann. Oncol. 13, 57-66.
29. Smith C.A., Gruss H.J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G.R., Brannan C.I., Copeland N.G., Jenkins N.A., Grabstein K.H., Gliniak B., McAlister I.B., Fanslow W., Alderson M., Falk B., Gimpel S., Gillis S., Din W.S., Goodwin R.G. and Armitage R.J. (1993). CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73, 1349-1360.
30. Trovato M., Villari D., Ruggeri R.M., Quattrocchi E., Fraggetta F., Simone A., Scarfi R., Magro G., Batolo D., Trimarchi F. and Benvenga S. (2001). Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules. Thyroid 11, 621-628.
31. Trovato M., Grosso M., Vitarelli E., Ruggeri R.M., Alesci S., Trimarchi F., Barresi G. and Benvenga S. (2003). Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Histol. Histopathol. 18, 393-399.
32. Watson P.F., Pickerill A.P., Davies R. and Weetman A.P. (1994). Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J. Clin. Endocrinol. Metab. 79, 355-360.
33. Weetman A.P. (2003). Grave's disease 1835-2002. Horm. Res. 59, 114-118.
34. Yokomuro S., Tsuji H., Lunz J.G. 3rd, Sakamoto T., Ezure T., Murase N. and Demetris AJ. (2000). Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 32, 26-35.
35. Zheng R.Q., Abney E., Chu C.Q., Field M., Grubeck-Loebenstein B., Maini R.N. and Feldmann M. (1991). Detection of interleukin-6 and interleukin-1 production in human thyroid epithelial cells by non-radioactive in situ hybridization and immunohistochemical methods. Clin. Exp. Immunol. 83, 314-319.